Record:   Prev Next
Author Montenegro, Pedro A
Title The Blood-Brain Barrier : New Research
Imprint Hauppauge : Nova Science Publishers, Incorporated, 2012
©2012
book jacket
Descript 1 online resource (346 pages)
text txt rdacontent
computer c rdamedia
online resource cr rdacarrier
Series Neuroscience Research Progress
Neuroscience Research Progress
Note Intro -- THE BLOOD-BRAIN BARRIER -- THE BLOOD-BRAIN BARRIER -- CONTENTS -- PREFACE -- LOCAL AND TEMPORAL REGULATION OF THE BLOOD-BRAIN BARRIER DURING NORMAL AND ALTERED PHYSIOLOGICAL STATES -- ABSTRACT -- INTRODUCTION -- BLOOD-BRAIN BARRIER STRUCTURE DURING NORMAL PHYSIOLOGICAL CONDITIONS -- Endothelial Cells -- Pericytes -- Astrocytes -- Microglia -- Basal Lamina -- Glycocalyx -- FUNCTIONAL SPECIALIZATIONS AT THE BLOOD-BRAIN BARRIERDURING NORMAL PHYSIOLOGICAL CONDITIONS -- Interendothelial Junctional Complex -- Transport Systems -- Endothelial Cell Transport Systems -- Astrocyte and Pericyte Junctional Complexes and Transport Systems -- BLOOD-BRAIN BARRIER STRUCTURE AND FUNCTION UNDERALTERED PHYSIOLOGICAL CONDITIONS -- Stress Effects on Blood-Brain Barrier Structure and Function -- Effects of Sleep Deprivation and Restriction upon Blood-Brain Barrier Function -- CONCLUSION -- REFERENCES -- ANGIOGENESIS AND ITS MECHANISTIC IMPLICATIONS IN THE PATHOLOGY OF NEURODEGENERATIVE DISORDERS -- ABSTRACT -- INTRODUCTION -- NORMAL STRUCTURE OF NEURAL VASCULATURE -- ANGIOGENESIS -- The Initiation Phase of Angiogenesis -- The Proliferation Phase of Angiogenesis -- The Maturation Phase of Angiogenesis -- ABNORMAL ANGIOGENESIS -- ANGIOGENIC INHIBITORS -- cyRGDfV -- TOXICITIES ASSOCIATED WITH ANGIOGENIC INHIBITORS -- ANGIOGENESIS AND ANGIOGENIC FACTORS IN MULTIPLE SCLEROSIS -- Evidence of Angiogenesis in Human MS -- Evidence of Angiogenesis in Experimental Models of MS -- ANGIOGENESIS AND ANGIOGENIC FACTORS INALZHEIMER'S DISEASE -- Evidence of Angiogenesis in Human AD -- Evidence of Angiogenesis in Experimental Models of AD -- Pathological Protein Deposits Modulate Angiogenesis -- Biomarker Studies -- Anti-Angiogenic Therapy in AD -- CONCLUSION -- Angiogenesis and Angiogenic Factors in Parkinson's Disease -- Evidence of Angiogenesis in Human PD
Evidence of Angiogenesis in Experimental Models of PD -- Biomarker Studies -- Anti-Angiogenic Agents Employed in PD Treatment -- Angiogenesis and Angiogenic Factors in Amyotrophic Lateral Sclerosis -- Evidence of Angiogenesis in Human ALS -- Biomarker Studies -- Anti-Angiogenic Therapies in ALS -- Angiogenesis and Angiogenic Factors in Huntington's Disease -- Angiogenesis and Angiogenic Factors in Neuroaids -- CONCLUSION -- REFERENCES -- IT TAKES TWO TO TANGO: PROTEIN-PROTEIN INTERACTIONS IN THE TRANSLOCATION OF PATHOGENS ACROSS A BLOOD-BRAIN BARRIER -- ABSTRACT -- 1. INTRODUCTION -- 2. A SPECIALIZED WALL "BLOOD-BRAIN BARRIER" AND ITS BUILDING BLOCKS: BRAIN MICROVASCULAR ENDOTHELIAL CELLS -- 3. SPECIAL FEATURES OF BBB AND ITS BULDING BLOCKS: THE BMECS -- 4. CROSSING OF THE WALL, TRANSCELLULAR VS. PARACELLULAR TRANSLOCATION -- 5. TRAVERSAL MECHANISMS AND HOST: PATHOGEN INTERACTIONS -- 5.1. Bacteria -- Esherichia Coli -- Group B Streptococci (GBS) -- Treponema pallidum -- Borrelia burgdorferi -- Mycobacterium tuberculosis -- Citrobacter spp. -- Listeria monocytogenes -- Chlamydiophila pneumoniae -- Other Neuroinvasive Bacteria -- 5.2. Fungi -- Cryptococcus neoformans -- Candida albicans -- Histoplasma capsulatum -- 5.3. Parasites -- Plasmodium falciparum -- Trypanosoma brucei -- Acanthomoeba -- Toxoplasma gondii -- 5.4. Viruses -- 6. PATHOGEN TRANSLOCATION AND ACTIVATION OF SIGNALING PATHWAY IN ECS -- ICAM-1 Signaling -- CD40 Signaling -- VCAM-1, PECAM-1 and ALCAM Signaling -- 7. EXPLOITATION OF HOST'S PROTEASES BY PATHOGENS TO DEGRADE ECM OF BBB -- Plasmin and Plasminogen Mediated BBB Translocation -- Metalloproteases Mediated BBB Crossing -- CONCLUSION -- ACKNOWLEDGMENTS -- REFERENCES -- EFFLUX-TRANSPORTERS AT THE BLOOD-BRAIN BARRIER: THERAPEUTIC OPPORTUNITIES -- ABSTRACT -- INTRODUCTION
The Blood-Brain Barrier: Biological Function and Functional Adaptations -- Tight Junctions: The Physical Barrier -- ABC Transporters: The Biochemical Barrier -- ABC TRANSPORTERS AT THE BLOOD-BRAIN BARRIERAND CENTRAL NERVOUS SYSTEM DISORDERS -- Inflammation -- Oxidative Stress -- Epilepsies -- Brain Cancer -- Alzheimer's Disease -- THERAPEUTIC OPPORTUNITIES -- CONCLUSION -- ACKNOWLEDGMENTS -- REFERENCES -- NOVEL STRATEGIES TO RESTORE BLOOD-BRAIN BARRIER INTEGRITY AFTER BRAIN INJURY -- ABSTRACT -- 1. INTRODUCTION -- Epidemiology, Current Therapies: Stroke, TBI -- 2. NOVEL PHARMACOLOGICAL TREATMENT STRATEGIES -- Glucocorticoid Insensitivity at the Hypoxic Blood Brain Barrier -- Alterations of the BBB in Brain Injury -- Mode of Action of GC -- GC Insensitivity of the Hypoxic BBB -- Cellular Protein Turnover after Brain Injury by the Ubiquitin-Proteasome System -- Post-Tranlational Modification of GR Protein by the Ubiquitin-Proteasome System -- GC Based Combination Therapy with Proteasomal Inhibitors to Treat Tissue Edema -- Monotherapies -- Summary -- 3. INHIBITION OF GLUCOSE TRANSPORTERS AT THE BBB -- Introduction -- Edema Formation after Brain Injury -- Role of Na+-Coupled Glucose Transporters of the SCL5a Family in BrainEdema Formation -- Experimental Models of Brain Injury -- Summary -- 4. TREATMENT STRATEGIES BASED ON MICRO-RNA -- MicroRNAs in Stroke and Traumatic Brain Injury -- ACKNOWLEDGMENTS -- REFERENCES -- EVALUATION OF THE BLOOD-CEREBROSPINALFLUID BARRIER IN NEUROLOGICAL DISEASES -- 1. BLOOD-CSF BARRIER -- 1.1. General Features -- 1.2. CSF Turnover Rate -- 1.3. CSF Reabsorption -- 1.4. Composition of the CSF -- 1.5. The Blood-CSF Barrier for Proteins -- 1.6. Evaluation of Blood-CSF Barrier Permeability -- A) Concentration Ratios -- B) CSF Protein Electrophoresis
2. EVALUATION OF BLOOD-CSF BARRIER PERMEABILITY IN AGING AND SOME NEUROLOGICAL DISEASES -- 2.1. Aging and Dementia -- 2.2. Stroke -- 2.3. Demyelinating Diseases -- A) Guillain Barré Syndrome -- B) Chronic Inflammatory Demyelinating Polyneuropathy -- C) Multiple Sclerosis -- D) Neuromyelitis Optica -- 2.4. Cuban Epidemic Optic Neuropathy (CEON) -- GENERAL CONSIDERATIONS -- REFERENCES -- BLOOD-BRAIN BARRIER IN HEALTH AND DISEASE -- ABSTRACT -- I. THE BLOOD-BRAIN BARRIER -- II. BRAIN MICROVASCULAR ENDOTHELIAL CELLS -- III. THE BLOOD-BRAIN BARRIER AS A SIGNALING INTERFACE -- IV. INTRACELLULAR SIGNALING PATHWAYS IN BRAIN ENDOTHELIAL CELLS -- V. ENDOTHELIAL INTERACTIONS IN THE NEUROVASCULAR UNIT -- VI. BLOOD-BRAIN BARRIER DISRUPTION IN BRAIN DISORDERS -- CONCLUSION -- ACKNOWLEDGMENTS -- REFERENCES -- CELL CULTURE MODELS OF THE BLOOD-BRAIN BARRIER: NEW RESEARCH -- ABSTRACT -- INTRODUCTION: THE BLOOD-BRAIN BARRIER -- STRUCTURE OF THE BLOOD-BRAIN BARRIER -- BRAIN MICROVASCULAR ENDOTHELIAL CELLS ANDTRANSPORTER MECHANISMS -- Junctional Complexes -- Transmembrane Proteins -- Cytoplasmic Proteins -- Cytoskeletal Proteins -- Astrocytes -- Pericytes -- IMMUNE CELL TRAFFICKING AT THE BLOOD-BRAIN BARRIER -- IN VITRO TISSUE-CULTURE BASED MODELS USED TO STUDY THE BLOOD-BRAIN BARRIER -- APPLICATIONS OF IN VITRO BBB SYSTEMS TO STUDY DRUG TRANSPORT TO THE BRAIN -- APPLICATIONS OF IN VITRO BBB SYSTEMS TO STUDY VIRALINTERACTIONS WITH THE BBB -- REFERENCES -- HIV-1 GP120 INDUCES BLOOD-BRAIN BARRIERABNORMALITIES: PATHOPHYSIOLOGY AND THERAPEUTIC CONSEQUENCES -- ABSTRACT -- INTRODUCTION -- HIV-1 GP120 DIRECTLY DAMAGES CNS BLOOD VESSELS -- GP120 IS DIRECTLY TOXIC TO BRAIN ENDOTHELIAL CELLS -- MMP PRODUCTION IS INCREASED AFTER GP120 INJECTION -- A. Gelatinolytic Activity Is Activated by Gp120 Administration
B. MMP-2 and MMP-9 Are Expressed Early in the Injured Striatum after Gp120 Injection -- GP120 INJECTION DEGRADES THE VASCULAR BASEMENT MEMBRANE AND VASCULAR TIGHT JUNCTIONS: RELATIONSHIPWITH MMPS ACTIVATION -- GP120 REDUCES THE NUMBEROF BRAIN MICROVESSELS -- NMDAR-1 ACTIVATION PLAYS A ROLE IN GP120-INDUCED BBB INJURY -- GP120 IN VIVO INDUCES OXIDATIVE STRESS IN ENDOTHELIALCELLS: GENE DELIVERY OF SOD1 AND GPX1 PROTECTS THE BBB FROM ACUTE GP120-RELATED INJURY -- ADMINISTRATION OF SV(GP120) INTO THE CP INDUCES BBB DISTURBANCES -- CONSEQUENCES OF BBB ABNORMALITIES FOR THE MIGRATIONOF HIV-1 INFECTED BLOOD CELLS INTO THE BRAIN -- CONCLUSION -- ACKNOWLEDGMENTS -- REFERENCES -- BLOOD BRAIN BARRIER IN HEPATIC ENCEPHALOPATHY -- ABSTRACT -- INTRODUCTION -- 1. BRAIN EDEMA -- 1.1. Cytotoxic Brain Edema -- 1.2. Vasogenic Edema -- 1.2.1. The Structure of Blood Brain Barrier -- 1.2.2. Change of Blood Brain Barrier in ALF -- 3. ENDOTOXIN AND TNF-Α IN ALF -- 3.1. Endotoxin -- 3.2. TNF-α -- 4. RECENT STUDIES ON THE BLOOD BRAIN BARRIER IN ALF -- REFERENCES -- BLOOD-BRAIN BARRIER (BBB): MORPHOLOGY AND DISEASE -- ABSTRACT -- 1. INTRODUCTION -- 2. MORPHOLOGY OF THE BLOOD-BRAIN BARRIER -- 3. EXPERIMENTAL MODELS IN MICE AND RATS TO IDENTIFY BBB MODIFICATIONS -- 3.1. Sucrose-Fed Metabolic Syndrome Model in Rats -- 3.2. Vanadium Inhalation Model -- CONCLUSION -- ACKNOWLEDGMENTS -- REFERENCES -- ROLE OF BLOOD-BRAIN BARRIER IN CEREBRAL MALARIA -- ABSTRACT -- 1. INTRODUCTION -- 2. PAST AND CURRENT THEORIES ON THE PATHOPHYSIOLOGYOF CM: AN ALMOST HUNDRED-YEAR-LONG JOURNEY -- 2.1. Mechanical Hypothesis -- 2.2. Permeability Hypothesis -- 2.3. Cytokine Hypothesis -- 2.4. Platelet Microparticle Hypotesis -- 3. SUPPORTING BBB PERMEABILITY HYPOTHESIS: EVIDENCE FROM HUMAN AND ANIMAL MODELS -- 3.1. In Vitro Evidence from Human or Animal BBB Models
3.2. In Vivo Evidence from Animal BBB Models
Description based on publisher supplied metadata and other sources
Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2020. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries
Link Print version: Montenegro, Pedro A. The Blood-Brain Barrier: New Research Hauppauge : Nova Science Publishers, Incorporated,c2012 9781621007661
Subject Blood-brain barrier
Electronic books
Alt Author Juárez, Stefanee M
Record:   Prev Next